DMSO and colchicine therapy in amyloid disease

M. A. Scheinberg, J. C. Pernambuco, M. D. Benson

Research output: Contribution to journalArticle

31 Scopus citations


There is no specific therapy for primary amyloidosis, and acquired generalised amyloidosis can be treated only if the underlying disease is eliminated. In this study we have investigated the role of colchicine therapy in primary amyloidosis, and dimethylsulphoxide (DMSO) in leprosy associated secondary amyloidosis. No effect on creatinine clearance or 24 h proteinuria could be observed in the patients with primary amyloidosis. In the DMSO group renal function was considerably improved in 3 patients with moderate renal failure but not in those with severe renal impairment (creatinine clearance < 10 ml/min). Serum SAA determinations were not particularly informative. These findings point to a beneficial effect of DMSO in human secondary amyloidosis when given at an early stage of renal involvement.

Original languageEnglish (US)
Pages (from-to)421-423
Number of pages3
JournalAnnals of the Rheumatic Diseases
Issue number3
StatePublished - 1984

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'DMSO and colchicine therapy in amyloid disease'. Together they form a unique fingerprint.

  • Cite this